Cannabis
Cannalogue Expands Compassionate Care Program to Provide Lowest Medical Cannabis Price in Canada
TORONTO, April 07, 2021 (GLOBE NEWSWIRE) — Doctor recommended medical CBD supplier, Cannalogue, has announced a significant price reduction for medical cannabis patients across Canada. As part of its expanded Compassionate Care Program, Cannalogue has secured the lowest per gram price for medical cannabis in Canada at $1.96/gram. Additionally, eligible new patients will receive 20% off their first order upon completion of a medical assessment.
With the most inclusive qualification criteria in Canada, Cannalogue’s Compassionate Care Program provides discounts of 20-50% on a wide range of medical cannabis products such as dried flower, oils, capsules, and topicals. Qualified groups include frontline workers, seniors (aged 60+), veterans, Indigenous peoples, first responders, nurses, teachers, those facing financial strain due to COVID-19 work shortage/layoffs, individuals currently enrolled in a disability, federal or provincial assistance program, and individuals with annual incomes less than $70,000 per year.
“We are living in times of unprecedented financial need, where cost is the key determinant in health decisions,” says Cannalogue President and CEO, Dr. Mohan Cooray. “With the lack of reasonable coverage, Cannalogue is doing all that we can to help our patients, and today is a gigantic leap forward in the quest towards affordable medical cannabis access for all Canadians,” he says.
To learn more about Cannalogue’s COVID-19 Compassionate Care Program or to enroll, visit www.cannalogue.ca/compassionate-care
About Cannalogue:
Based in Toronto, Cannalogue is a rapidly emerging global healthcare technology company that received Health Canada’s first direct-to-sales licence for medical cannabis. Cannalogue’s innovative technology provides a safe, controlled, and cost-effective online marketplace that is globally scalable into all medical cannabis markets. Engineered by physicians, Cannalogue challenges the status quo and advocates on behalf of patients to educate medical professionals and government officials on the safety and benefits of medical cannabis as a viable treatment option to traditional therapies.
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis3 days ago
Rubicon Organics Reports Q1 2024 Financial Results